PhRMA Will Keep Focus On Innovation, Access To Protect The Castle, New Chairman Suggests
Executive Summary
Incoming PhRMA Chairman Robert Hugin, CEO of Celgene, outlines the organization’s advocacy priorities for protecting innovation and patient access to medicines, emphasizing “we have to have a good defense; we have to play this part of the game.”
You may also be interested in...
FDA’s 8.2% Solution: Sequestration Would Cut $319 Million
The estimated reduction, included in the White House Office of Management and Budget’s report to Congress, is equal the cost of 900 to 1,200 agency employees, an agency advocate said.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.
Biden vs Trump On Drug Pricing And Unfinished Business
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.